Acquisition Momentum Recent acquisition by RTI Surgical (Oct 2024) indicates a strategic consolidation in the regenerative medicine and biomaterials space, presenting opportunities to align with RTI’s extended portfolio and cross-sell collagen-based tissues and biomaterials.

Regenerative Focus Strong emphasis on collagen, tissues and biomaterials for regenerative medicine and medical devices across orthopedics, cardiovascular, dental, wound care and neurology creates upsell potential with manufacturers and device developers seeking advanced scaffolds and engineered tissues.

Geographic Expansion History of facility expansion in Glasgow and Europe plus ongoing global supply capabilities suggests readiness to support European and international customers with scalable manufacturing, enabling new regional partnerships.

Financial Scale Revenue in the mid tens-of-millions range with global supplier role indicates viability for long-term contract manufacturing and collaboration deals with larger biotech and device companies seeking reliable biomaterial sourcing.

Tech & Collaboration Diverse tech stack and regulatory-focused development capabilities position Evergen to partner with R&D teams for custom scaffolds, contract development manufacturing, and co-development programs with biomaterials and surgical device players.